Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26262868 | 0.77 | MAP4K4 (0.61) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL10974762 | 0.76 | CHEK1 (0.60) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL837257 | 0.75 | MAPT (0.53) | SMN1; SMN2MAPTAGTR1GAAKDM4E | |
| SCHEMBL2698364 | 0.74 | ACHE (0.49) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL398019 | 0.73 | MAP4K4 (0.61) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL25867792 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL27481130 | 0.72 | WNT3A (0.51) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| Hydrochloric Acid SCHEMBL18605713 | 0.71 | MAP4K4 (0.59) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL15614090 | 0.71 | MAP4K4 (0.59) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL2117282 | 0.70 | NPC1 (1.00) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | NAT CENTRE FOR BIOLOGICAL SCIENCES TIFR (IN) | 2022-03-03 | — | — | US | disclosed |
| US-8252841-B2 | Methods of inhibiting bacterial virulence and compounds relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2010-02-25 | — | — | US | disclosed |
| US-4209621-A | TRANQUILIZERS | AMERICAN CYANAMID COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | MMP8, SLC11A2, NFKBIA | SMN1; SMN2 4873/4885RAB9A 1273/4885NPC1 2741/4885 |
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | CD4, CD14, CD69 | SMN1; SMN2 4574/4885RAB9A 997/4885NPC1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.